Taysha Gene Therapies, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on the stock and has a $8.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tazeen Ahmad has given his Buy rating due to a combination of factors that highlight the promising prospects of Taysha Gene Therapies. The company has finalized the pivotal trial design for their gene therapy, TSHA-102, aimed at treating Rett syndrome. This trial includes a 6-month interim readout, which could potentially accelerate the approval process by six months, positioning TSHA-102 as a frontrunner in the market.
Furthermore, the trial’s manageable success threshold and the promising results from the earlier phase, where a high responder rate was achieved, contribute to the positive outlook. Additionally, the FDA’s granting of Breakthrough Therapy designation to TSHA-102 underscores its potential as a pioneering treatment for Rett syndrome, addressing a significant unmet medical need. These strategic advancements and regulatory endorsements support the Buy rating, with a price objective set at $8.00 USD.
In another report released today, Needham also reiterated a Buy rating on the stock with a $10.00 price target.